Vonoprazan impurities: the four questions that decide a generic filing
· Impurity control · CATO technical documentation
Vonoprazan is a potassium-competitive acid blocker, and as its originator patents run out, the number of generic filings rises with it. In those filings the impurity section — not the assay, not the dissolution profile — is where submissions come back with questions. The same four categories of question keep reappearing, and each one is answered with documentation rather than with an argument.
1. Where did this impurity come from?
Every declared impurity has to be assigned an origin: process impurity, degradation product, or both. Reviewers ask for the evidence, not the assertion.
- A forced-degradation study (acid, base, oxidation, thermal, photolytic) that shows the impurity
appearing, with the degradation route written out.
- A correlation between the impurity found in forced-degradation samples and the impurity found in
aged or stressed drug product — same retention time is not proof; the correlation should be supported by a spiked sample or by mass-spectrometric confirmation.
- A mass balance that accounts for the degradation products, rather than a list of "potential
impurities" that no experiment has ever produced.
An impurity that is claimed as a process impurity but appears only in stressed samples is the most common place where a filing stalls.
2. Is the structure actually established?
For vonoprazan, as for most small-molecule APIs, the difficult impurities are structural isomers: same molecular formula, same nominal mass, different connectivity. Chromatographic behaviour alone does not distinguish them, and neither does a single-stage mass spectrum.
| Evidence | Establishes |
|---|---|
| LC-MS (single stage) | molecular mass, and that the peak is a distinct component |
| HRMS | the molecular formula, and therefore the candidate isomer set |
| Forced degradation + spiking | which route produces it, and whether it matches |
| Preparative isolation | enough material to run spectroscopy on |
| NMR (1D and 2D) | the connectivity — this is what settles an isomer assignment |
| Authentic reference standard | that the assigned structure and the peak are the same substance |
The last row is the one that matters commercially: an assignment is only as good as the material it was made against. Without an authentic standard the assignment cannot be transferred to a routine method.
3. Is the standard fit for the purpose it is used for?
A reference standard used to identify a peak and a reference standard used to quantify it are held to different requirements. For quantitation the certificate has to state an assigned content per lot — a mass fraction with its analytical basis — because that number converts a peak area into a mass. A nominal "purity: 98%" figure does not.
What a reviewer expects to see on file for each impurity standard:
- Catalogue number, lot number and the assigned content for that lot.
- The analytical basis of the assignment (mass balance, qNMR, or both) and the uncertainty.
- Storage condition, and a retest or expiry statement.
- A safety data sheet that carries the transport classification, for shipping and for the laboratory's
own records.
4. Does the method resolve what it claims to resolve?
If two isomers are both declared, the method has to separate them, and the validation has to show it — resolution, specificity against the other declared impurities and against the placebo, and stability of the standard solutions over the run. Isomer pairs that are not resolved by the submitted method produce a deficiency question even when the chemistry is correct.
What CATO supplies
CATO manufactures vonoprazan-related impurities and issues a certificate of analysis per lot, with the assigned content stated for that lot. Where a filing needs an impurity that is not in our catalogue, our custom synthesis group takes the structure — from the deficiency letter, the degradation study or the proposed route — and confirms what can be supplied from stock and what has to be made.
If you are working through a vonoprazan submission, the fastest route is to send the list of declared impurities with their structures, or the deficiency question itself. We will come back with what we can supply, the documentation that travels with it, and the lead time — see the catalogue for the items already listed.
*CATO publishes its own technical notes. Background on the vonoprazan impurity topic comes from CATO's own industry notes; the four categories above are the ones we see recurring in filing correspondence, and every recommendation here is about documentation a laboratory can hold itself.*
Written by CATO. Where a claim depends on an external source we say which one; where it depends on our own catalogue we name the catalogue number so you can check it. Spotted an error? Email chao.lu@cato-chem.com — corrections are published in place.